← All trials
NCT05704543
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2023
- Primary completion
- Oct 23, 2023
- Completion date
- Oct 23, 2023
- First posted
- Jan 30, 2023
- Last posted
- Nov 2, 2023
- Enrollment
- 88
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Indivior Inc.Lead sponsor
- Indivior Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.